Claims for Patent: 9,815,820

Summary for Patent: 9,815,820

Title:	Rho kinase inhibitors
Abstract:	The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2.
Inventor(s):	Poyurovsky; Masha (New York, NY), Kim; Ji-In (Princeton, NJ), Liu; Kevin (West Windsor, NJ), Zanin-Zhorov; Alexandra (Staten Island, NY)
Assignee:	Kadmon Corporation, LLC (New York, NY)
Application Number:	14/431,936
Patent Claims:	1. A compound of Formula XVI: ##STR00221## or pharmaceutically acceptable salt thereof, wherein: R.sup.13 and R.sup.14 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic or aromatic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, oxo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6, alkenyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.6 alkoxy, CN and C.sub.1-C.sub.3 perfluoro alkyl; or R.sup.13 and R.sup.14 may be taken together form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6, alkenyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.7 cycloalkyl, oxo, --OH, --NH.sub.2, CN and C.sub.1-C.sub.3 perfluoro alkyl; R.sup.2 is selected from H and halo; each R.sup.3 and R.sup.4 is independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, --CN, halo, --OH, --O--(C.sub.1-C.sub.6 alkyl), --O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --NR.sup.31R.sup.32, C.sub.1-C.sub.3 perfluoro alkyl, --O--(CH.sub.2).sub.aNR.sup.31R.sup.32, --NR.sup.31--(CH.sub.2).sub.aNR.sup.33R.sup.34, --NR.sup.31--(CH.sub.2).sub.aOR.sup.33, aryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, and --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl); R.sup.31 and R.sup.32 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, and --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl); or R.sup.31 and R.sup.32 may be taken together to form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; R.sup.33 and R.sup.34 are independently selected from the group consisting of H and C.sub.1-C.sub.8 alkyl; a is selected from 0 to 6; R.sup.5 is selected from H and C.sub.1-C.sub.6 alkyl; R.sup.6 is selected from the group consisting of H, halo, and C.sub.1-C.sub.6 alkyl. 2. A compound of Formula XVII: ##STR00222## or pharmaceutically acceptable salt thereof, wherein: X is selected from the group consisting of --NH--C(.dbd.O)--CHR.sup.13R.sup.14; --NH--C(.dbd.O)--(CH.sub.2).sub.b--NR.sup.13R.sup.14; --C(.dbd.O)--NR.sup.13R.sup.14; R.sup.13 and R.sup.14 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), aryl, heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, oxo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6, alkenyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.6 alkoxy, CN and C.sub.1-C.sub.3 perfluoro alkyl; each R.sup.3 and R.sup.4 is independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, --CN, halo, --OH, --O--(C.sub.1-C.sub.6 alkyl), --O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --NR.sup.31R.sup.32, C.sub.1-C.sub.3 perfluoro alkyl, --O--(CH.sub.2).sub.aNR.sup.31R.sup.32, aryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; R.sup.31 and R.sup.32 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, and --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl); a is selected from 0 to 6; b is selected from 0 to 1. 3. A compound of Formula XVIII: ##STR00223## or pharmaceutically acceptable salt thereof, wherein: each R.sup.3 and R.sup.4 is independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, --CN, halo, --OH, --O--(C.sub.1-C.sub.6 alkyl), --O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --NR.sup.31R.sup.32, C.sub.1-C.sub.3 perfluoro alkyl, --O--(CH.sub.2).sub.aNR.sup.31R.sup.32, aryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; R.sup.31 and R.sup.32 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, and --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl); a is selected from 0 to 6; R.sup.15 is selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, --CN, halo, --OH, --O--(C.sub.1-C.sub.6 alkyl), --O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --C(.dbd.O)--O--C(R).sub.331, C.sub.1-C.sub.3 perfluoro alkyl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic or aromatic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; x is selected from 1 to 3; y is selected from 0 to 3; z is selected from 0 to 3; wherein y or z are independently selected and one of which is at least 1. 4. A compound of Formula XIX: ##STR00224## or pharmaceutically acceptable salt thereof, wherein: R.sup.13 and R.sup.14 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic or aromatic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, oxo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6, alkenyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.6 alkoxy, CN and C.sub.1-C.sub.3 perfluoro alkyl; or R.sup.13 and R.sup.14 may be taken together form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.7 cycloalkyl, oxo, --OH, --NH.sub.2, CN and C.sub.1-C.sub.3 perfluoro alkyl; Y is selected from the group consisting of S, CH.sub.2, and --CR.sup.31R.sup.32--; R.sup.2 is selected from H and halo; each R.sup.3 and R.sup.4 is independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, --CN, halo, --OH, --O--(C.sub.1-C.sub.6 alkyl), --O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --NR.sup.31R.sup.32, C.sub.1-C.sub.3 perfluoro alkyl, --O--(CH.sub.2).sub.aNR.sup.31R.sup.32, --NR.sup.31--(CH.sub.2).sub.aNR.sup.33R.sup.34, --NR.sup.31--(CH.sub.2).sub.aOR.sup.33, aryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, and --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl); R.sup.31 and R.sup.32 are independently selected from the group consisting of H, halo, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, and --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl); or R.sup.31 and R.sup.32 may be taken together to form a three to twelve membered cycloalkyl or heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; R.sup.33 and R.sup.34 are independently selected from the group consisting of H and C.sub.1-C.sub.8 alkyl; a is selected from 0 to 6. 5. A compound of Formula XX: ##STR00225## or pharmaceutically acceptable salt thereof, wherein: R.sup.13 and R.sup.14 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic or aromatic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, oxo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6, alkenyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.6 alkoxy, CN and C.sub.1-C.sub.3 perfluoro alkyl; or R.sup.13 and R.sup.14 may be taken together form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6, alkenyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.7 cycloalkyl, oxo, --OH, --NH.sub.2, CN and C.sub.1-C.sub.3 perfluoro alkyl; R.sup.4 is selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, --CN, halo, --OH, --O--(C.sub.1-C.sub.6 alkyl), --O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --NR.sup.31R.sup.32, C.sub.1-C.sub.3 perfluoro alkyl, --O--(CH.sub.2).sub.aNR.sup.31R.sup.32, aryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; R.sup.31 and R.sup.32 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, and --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl); or R.sup.31 and R.sup.32 may be taken together to form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; R.sup.5 is selected from H and C.sub.1-C.sub.6 alkyl. 6. A compound of Formula XXI: ##STR00226## or pharmaceutically acceptable salt thereof, wherein: R.sup.13 and R.sup.14 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic or aromatic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, oxo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6, alkenyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.6 alkoxy, CN and C.sub.1-C.sub.3 perfluoro alkyl; or R.sup.13 and R.sup.14 may be taken together form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6, alkenyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.7 cycloalkyl, oxo, --OH, --NH.sub.2, CN and C.sub.1-C.sub.3 perfluoro alkyl; R.sup.4 is selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, --CN, halo, --OH, --O--(C.sub.1-C.sub.6 alkyl), --O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --NR.sup.31R.sup.32, C.sub.1-C.sub.3 perfluoro alkyl, --O--(CH.sub.2).sub.aNR.sup.31R.sup.32, aryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; R.sup.31 and R.sup.32 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, and --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl); or R.sup.31 and R.sup.32 may be taken together to form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; a is selected from 0 to 6. 7. A compound of Formula XXII: ##STR00227## or pharmaceutically acceptable salt thereof, wherein: R.sup.13 and R.sup.14 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic or aromatic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, oxo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6, alkenyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.6 alkoxy, CN and C.sub.1-C.sub.3 perfluoro alkyl; or R.sup.13 and R.sup.14 may be taken together form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6, alkenyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.7 cycloalkyl, oxo, --OH, --NH.sub.2, CN and C.sub.1-C.sub.3 perfluoro alkyl; R.sup.3 is H; R.sup.4 is selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, --CN, halo, --OH, --O--(C.sub.1-C.sub.6 alkyl), --O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --NR.sup.31R.sup.32, C.sub.1-C.sub.3 perfluoro alkyl, --O--(CH.sub.2).sub.aNR.sup.31R.sup.32, aryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; R.sup.31 and R.sup.32 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, and --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl); or R.sup.31 and R.sup.32 may be taken together to form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; a is selected from 0 to 6. 8. A compound of Formula XXIII: ##STR00228## or pharmaceutically acceptable salt thereof, wherein: R.sup.13 and R.sup.14 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic or aromatic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, oxo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6, alkenyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.6 alkoxy, CN and C.sub.1-C.sub.3 perfluoro alkyl; or R.sup.13 and R.sup.14 may be taken together form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6, alkenyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.7 cycloalkyl, oxo, --OH, --NH.sub.2, CN and C.sub.1-C.sub.3 perfluoro alkyl; x is selected from 0 to 1; R.sup.2 is selected from the group consisting of cyclohexylpyridine, 1H-pyrazole, and pyridine; ##STR00229## X is selected from N or CR.sup.3; Y is selected from N or CR.sup.3; Z is selected from N or CR.sup.4; wherein at least one of X, Y, and Z is N; R.sup.4 is selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, --CN, halo, --OH, --O--(C.sub.1-C.sub.6 alkyl), --O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --NR.sup.31R.sup.32, C.sub.1-C.sub.3 perfluoro alkyl, --O--(CH.sub.2).sub.aNR.sup.31R.sup.32, --NR.sup.31--(CH.sub.2).sub.aNR.sup.33R.sup.34, --NR.sup.31--(CH.sub.2).sub.aOR.sup.33, aryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, and --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl); R.sup.31 and R.sup.32 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, and --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl); or R.sup.31 and R.sup.32 may be taken together to form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; a is selected from 0 to 6; Q is selected from the group NR.sup.5 and O; R.sup.5 is selected from H and C.sub.1-C.sub.6 alkyl. 9. A compound of Formula XXIV: ##STR00230## or pharmaceutically acceptable salt thereof, wherein: R.sup.12 is selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), amino, NR.sup.31R.sup.32, heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic or aromatic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, oxo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6, alkenyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.6 alkoxy, CN and C.sub.1-C.sub.3 perfluoro alkyl; x is selected from 0 to 2; each R.sup.3 and R.sup.4 is independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, --CN, halo, --OH, --O--(C.sub.1-C.sub.6 alkyl), --O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --NR.sup.31R.sup.32, C.sub.1-C.sub.3 perfluoro alkyl, --O--(CH.sub.2).sub.aNR.sup.31R.sup.32, aryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; R.sup.31 and R.sup.32 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, C.sub.3-C.sub.7 cycloalkyl and C.sub.3-C.sub.7 cycloalkyl --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl); or R.sup.31 and R.sup.32 may be taken together to form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; a is selected from 1 to 6. 10. A compound of Formula XXV: ##STR00231## or pharmaceutically acceptable salt thereof, wherein: R.sup.13 and R.sup.14 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic or aromatic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, oxo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6, alkenyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.6 alkoxy, CN and C.sub.1-C.sub.3 perfluoro alkyl; or R.sup.13 and R.sup.14 may be taken together form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6, alkenyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.7 cycloalkyl, oxo, --OH, --NH.sub.2, CN and C.sub.1-C.sub.3 perfluoro alkyl; x is selected from 0 to 3; R.sup.15 is selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, aryl, heteroaryl, heterocyclic ring, and C.sub.3-C.sub.7 cycloalkyl; each R.sup.3 and R.sup.4 is independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, --CN, halo, --OH, --O--(C.sub.1-C.sub.6 alkyl), --O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --NR.sup.31R.sup.32, C.sub.1-C.sub.3 perfluoro alkyl, --O--(CH.sub.2).sub.aNR.sup.31R.sup.32, aryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; R.sup.31 and R.sup.32 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, and --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl); or R.sup.31 and R.sup.32 may be taken together to form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted from 1 to 3 substituents independently selected from halo and C.sub.1-C.sub.6 alkyl; a is selected from 1 to 6. 11. A method of treating an autoimmune disorder in a subject comprising: administering to the subject a therapeutically effective amount of a compound that inhibits ROCK2. 12. The method of claim 1, wherein the autoimmune disorder is rheumatoid arthritis, (multiple sclerosis), systemic lupus erythematosus (SLE; lupus), psoriasis, Crohn's disease, atopic dermatitis, eczema, or graft-versus-host disease (GVHD). 13. The method of claim 11, wherein the compound that inhibits ROCK2 is a compound of the formula: ##STR00232## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is selected from the group consisting of --O--(CH.sub.2).sub.y--CO.sub.2R.sup.12, --O--(CH.sub.2).sub.y--C(.dbd.O)NR.sup.13R.sup.14, --O--(CH.sub.2)-heteroaryl, --O--(CH.sub.2)-cycloalkyl, --O--C(.dbd.O)--(CH.sub.2).sub.y--NR.sup.13R.sup.14, --O--(CH.sub.2).sub.z-NR.sup.13R.sup.14, --NH--C(.dbd.O)--(CH.sub.2)--NR.sup.13R.sup.14, --NH--C(.dbd.O)--X--R.sup.5, --NH--(CH.sub.2).sub.y--NR.sup.13R.sup.14; R.sup.12 is selected from the group consisting of C.sub.1-C.sub.6 alkyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6 alkyl)-NR.sup.16R.sup.17, --(C.sub.1-C.sub.6 alkyl)-C(.dbd.O)NR.sup.16R.sup.17, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), aryl, aralkyl, heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring containing up to 3 heteroatoms, each of which may be optionally substituted at one or more carbon atoms by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkoxy, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; R.sup.13 and R.sup.14 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6 alkyl)-NR.sup.16R.sup.17, --(C.sub.1-C.sub.6 alkyl)-C(.dbd.O)NR.sup.16R.sup.17, aryl, aralkyl, heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.6 alkoxy, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; or R.sup.13 and R.sup.14 may be taken together to form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.7 cycloalkyl, oxo, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; X is selected from a covalent bond, O, NH, and C.sub.1-C.sub.6 alkyl; R.sup.15 is selected from the group consisting of heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkoxy, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl, or R.sup.15 is selected from --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6 alkyl)-NR.sup.16R.sup.17, --CO.sub.2R.sup.18, --O--(CH.sub.2).sub.x-CO.sub.2R.sup.18, and --C(.dbd.O)NR.sup.16R.sup.17; R.sup.16 and R.sup.17 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), aryl, aralkyl, heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkoxy, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; or R.sup.16 and R.sup.17 may be taken together to form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkoxy, oxo, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; R.sup.18 is selected from the group consisting of H, aryl, aralkyl, heteroaryl, C.sub.1-C.sub.6 alkyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6 alkyl)-NR.sup.16R.sup.17, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkoxy, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoroalkyl; x is selected from 0 to 6; y is selected from 0 to 6; z is selected from 2 to 6; each R.sup.2 is independently selected from the group consisting of lower alkyl, CN, halo, hydroxy, lower alkoxy, amino, and perfluoro lower alkyl; each R.sup.3 is independently selected from the group consisting of lower alkyl, CN, halo, hydroxy, lower alkoxy, amino, and perfluoro lower alkyl; R.sup.4 is selected from H, --(CH.sub.2).sub.a--NR.sup.43R.sup.44, --Y--R.sup.42, --O--(CH.sub.2).sub.a--CO.sub.2R.sup.42, --O--(CH.sub.2).sub.a--C(.dbd.O)NR.sup.43R.sup.44, --O--(CH.sub.2).sub.a-heteroaryl, --O--(CH.sub.2).sub.a-cycloalkyl, --O--C(.dbd.O)--(CH.sub.2).sub.a--NR.sup.43R.sup.44, --O--(CH.sub.2).sub.c--NR.sup.43R.sup.44, --NH--C(.dbd.O)--(CH.sub.2).sub.a--NR.sup.43R.sup.44, --NH--C(.dbd.O)--Y--R.sup.45, --NH--C(.dbd.O)--(CH.sub.2).sub.a--NR.sup.43R.sup.44; R.sup.42 is selected from the group consisting of C.sub.1-C.sub.6 alkyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6 alkyl)-NR.sup.46R.sup.47, --(C.sub.1-C.sub.6 alkyl)-C(.dbd.O)NR.sup.46R.sup.47, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), each of which may be optionally substituted at one or more carbon atoms by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkoxy, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; R.sup.43 and R.sup.44 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6 alkyl)-NR.sup.46R.sup.47, --(C.sub.1-C.sub.6 alkyl)-C(.dbd.O)NR.sup.46R.sup.47, aryl, aralkyl, heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.6 alkoxy, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; or R.sup.43 and R.sup.44 may be taken together to form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkoxy, oxo, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; Y is selected from a covalent bond, O, NH, and C.sub.1-C.sub.6 alkyl; R.sup.45 is selected from the group consisting of H, aryl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6 alkyl)-NR.sup.46R.sup.47, --CO.sub.2R.sup.48, --O--(CH.sub.2).sub.b--CO.sub.2R.sup.48, and --C(.dbd.O)NR.sup.46R.sup.47, R.sup.46 and R.sup.47 independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), aryl, aralkyl, heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkoxy, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; or R.sup.46 and R.sup.47 may be taken together to form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkoxy, oxo, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; R.sup.48 is selected from the group consisting of H, aryl, aralkyl, heteroaryl, C.sub.1-C.sub.6 alkyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6 alkyl)-NR.sup.46R.sup.47, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkoxy, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoroalkyl; a is selected from 0 to 6; b is selected from 0 to 6; c is selected from 2 to 6; R.sup.5 is selected from the group consisting of H, C.sub.1-C.sub.6 alkyl, --(CH.sub.2).sub.d--C(.dbd.O)--NR.sup.53R.sup.54, --C(.dbd.O)--(CH.sub.2).sub.d--NR.sup.53R.sup.54, --C(.dbd.O)--X--R.sup.55, and --C(.dbd.O)--(CH.sub.2).sub.d--NR.sup.53R.sup.54; R.sup.53 and R.sup.54 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6 alkyl)-NR.sup.56R.sup.57, --(C.sub.1-C.sub.6 alkyl)-C(.dbd.O)NR.sup.56R.sup.57, aryl, aralkyl, heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.6 alkoxy, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; or R.sup.53 and R.sup.54 may be taken together to form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.7 cycloalkyl, oxo, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; R.sup.55 is selected from the group consisting of H, aryl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6 alkyl)-NR.sup.56R.sup.57, --CO.sub.2R.sup.58, --O--(CH.sub.2).sub.e--CO.sub.2R.sup.58, and --C(.dbd.O)NR.sup.56R.sup.57, R.sup.56 and R.sup.57 independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), aryl, aralkyl, heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkoxy, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; or R.sup.56 and R.sup.57 may be taken together to form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkoxy, oxo, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; R.sup.58 is selected from the group consisting of H, aryl, aralkyl, heteroaryl, C.sub.1-C.sub.6 alkyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6 alkyl)-NR.sup.56R.sup.57, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkoxy, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoroalkyl; d is selected from 0 to 6; e is selected from 0 to 6; R.sup.6 is selected from the group consisting of H, C.sub.1-C.sub.6 alkyl, --(CH.sub.2).sub.r--C(.dbd.O)--NR.sup.63R.sup.64, --C(.dbd.O)--(CH.sub.2).sub.r--NR.sup.63R.sup.64, --C(.dbd.O)--X--R.sup.65, and --C(.dbd.O)--(CH.sub.2).sub.r--NR.sup.63R.sup.64; R.sup.63 and R.sup.64 are independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6 alkyl)-NR.sup.66R.sup.67, --(C.sub.1-C.sub.6 alkyl)-C(.dbd.O)NR.sup.66R.sup.67, aryl, aralkyl, heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.6 alkoxy, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; or R.sup.63 and R.sup.64 may be taken together to form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.7 cycloalkyl, oxo, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; R.sup.65 is selected from the group consisting of H, aryl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6 alkyl)-NR.sup.66R.sup.67, --CO.sub.2R.sup.68, --O--(CH.sub.2).sub.s--CO.sub.2R.sup.68, and --C(.dbd.O)NR.sup.66R.sup.67, R.sup.66 and R.sup.67 independently selected from the group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), aryl, aralkyl, heteroaryl, C.sub.3-C.sub.7 cycloalkyl, a three to twelve membered heterocyclic ring containing up to 3 heteroatoms, each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkoxy, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; or R.sup.66 and R.sup.67 may be taken together to form a three to twelve membered heterocyclic ring having up to 3 heteroatoms which is optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.1-C.sub.6 alkoxy, oxo, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoro alkyl; R.sup.68 is selected from the group consisting of H, aryl, aralkyl, heteroaryl, C.sub.1-C.sub.6 alkyl, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6 alkyl)-NR.sup.66R.sup.67, --(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl)-O--(C.sub.1-C.sub.6 alkyl), each of which may be optionally substituted by from 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.6 alkoxy, hydroxy, amino, cyano and C.sub.1-C.sub.3 perfluoroalkyl; r is selected from 0 to 6; s is selected from 0 to 6; n is selected from 0 to 4; m is selected from 0 to 3; and p is selected from 0 and 1. 14. The method of claim 11, wherein the compound that inhibits ROCK2 is a compound of the formula ##STR00233##